TCL Archive Von Eschenbach takes leave of absence from NCI, resigns from C-Change board. Acting FDA commissioner’s drug approval strategy rooted in unproven science. Von Eschenbach told NCI deputies he might drop in on meetings. Who’s really in charge? October 7, 2005
TCL Archive IOM Omics Committee Offers Blueprint to Prevent Other Duke-Style Disasters March 23, 2012
TCL Archive In Brief: Cavenee Is President-elect of AACR; Coffey To Succeed Strong As President April 11, 1997
